It is possible that tumour-infiltrating granulocytes promote tumour progression.
Several lines of evidence indicate that tumour-infiltrating granulocytes (TIGs) promote tumour growth and progression. However, the prognostic significance of TIGs, the relationship between TIGs and Fas ligand (FasL) expressed on tumour cells remains unclear and warrants investigation. Using immunnostaining, we retrospectively investigated TIGs and FasL in 130 tissue specimens from gastric carcinoma. We analyzed the correlation among these markers, their association with clinicopathologic features and prognosis. The number of TIGs was significantly associated with FasL-expression (P=0.002). Further, TIGs were significantly associated with depth of tumour invasion, lymph node metastasis and tumour stage. Calculating the prognostic relevance, in multivariate analysis, TIGs [relative risk (RR)=1.014; 95% CI=1.002-1.027; P=0.015] and tumour stage were statistically significant factors for survival. Our results suggest that TIGs are conveniently measured by the immunostaining method, and possibly serve as an independent factor of prognosis in patients with gastric carcinoma. This is based on the fact that TIGs were significantly associated with tumour stage and shorter survival time.
Liu
Huanran
H
Fourth Department of Surgery, Kasumigaura Hospital Tokyo Medical University, Inashiki-Gun, Ibaragi, Japan. lhrlhr9050@yahoo.com
Ubukata
Hideyuki
H
Tabuchi
Takanobu
T
Takemura
Akira
A
Motohashi
Gyou
G
Nishimura
Motoi
M
Satani
Tetsuro
T
Hong
Jianwei
J
Katano
Motonobu
M
Nakada
Ichiro
I
Saniabadi
Abbi R
AR
Tabuchi
Takafumi
T
D000230:Adenocarcinoma / Q000276:immunology* / Q000556:secondary / Q000601:surgery; D000368:Aged; D018450:Disease Progression; D053222:Fas Ligand Protein / Q000032:analysis; D005260:Female; D005743:Gastrectomy; D006098:Granulocytes / Q000276:immunology*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000276:immunology* / Q000473:pathology / Q000601:surgery; D013997:Time Factors; D016896:Treatment Outcome
C505661:FASLG protein, human; D053222:Fas Ligand Protein